According to a report in the New York Post, a recent study by Stanford University researchers has uncovered a “new category of depression” that it claims affects about 27% of those who have been diagnosed. According to the study, conventional antidepressant drugs are ineffective in treating this specific sort of depression.
This distinct kind of depression, which researchers have dubbed “cognitive,” shares many traits with attention deficit disorders. According to the site, people who experience this kind of depression frequently struggle with self-control, planning ahead, staying focused in the face of distractions, and having trouble repressing improper behaviour.
Serotonin levels in the brain are often the focus of traditional antidepressants. But according to Stanford researchers, this method is “less effective for patients with cognitive dysfunction” like those who have been identified with this brand-new depression variation.
According to lead author Leanne Williams, “one of the big challenges is to find a new way to address what is currently a trial-and-error process so that more people can get better sooner.”
The report is based on a randomised clinical trial involving more than 1,000 adults who received therapy to balance serotonin levels since many scientists think that serotonin imbalances are a major factor in depression. Only 38% of those with the novel syb-type of depression experienced symptom remission, compared to approximately 48% of those without it, according to Stanford researchers.
The first instance of a “clinically actionable cognitive biotype of depression” has been found, according to the researchers, and this finding. Their findings suggest that a decline in cognitive performance can both contribute to the development of depression and be a symptom of it.